{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:55:23Z","timestamp":1780667723723,"version":"3.54.1"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHC"],"DOI":"10.2147\/jhc.s169285","type":"journal-article","created":{"date-parts":[[2018,11,18]],"date-time":"2018-11-18T19:22:26Z","timestamp":1542568946000},"page":"109-119","source":"Crossref","is-referenced-by-count":20,"title":["Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)"],"prefix":"10.2147","volume":"Volume 5","author":[{"given":"Hamdy","family":"Azim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Omar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Atef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Zawahry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0199-074X","authenticated-orcid":true,"given":"Mohamed K","family":"Shaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7948-2676","authenticated-orcid":true,"given":"AH Kamel","family":"Abdelmaksoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"EzzElarab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-2502","authenticated-orcid":true,"given":"Omar","family":"Abdel-Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6559-5867","authenticated-orcid":true,"given":"Loay","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9857-8972","authenticated-orcid":true,"given":"Imam","family":"Waked","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,11]]},"container-title":["Journal of Hepatocellular Carcinoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=46294","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=46294","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,18]],"date-time":"2018-11-18T19:22:27Z","timestamp":1542568947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/sorafenib-plus-tegafur-uracil-uft-versus-sorafenib-as-first-line-syste-peer-reviewed-article-JHC"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/jhc.s169285","relation":{},"ISSN":["2253-5969"],"issn-type":[{"value":"2253-5969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}